No news on the trials is actually good news. We would have heard by now if it had gone off the rails. A few more weeks is not unreasonable to analyse the results, write the report, review it and approve it, and publish it.
As for a partner deal, TIS is better off not giving a target date as that would (again) put it in a weaker bargaining position leading up to any target date.
Patience all, it should be a great year.
TIS Price at posting:
58.5¢ Sentiment: Buy Disclosure: Held
